Stellar Pharmaceuticals Appoints Chief Scientific Officer to
Stellar Pharmaceuticals Appoints Chief Scientific Officer to Support Growing Product Portfolio
Dr. Bernard Chiasson held Senior Medical Positions at United Health, Amgen, Bayer Canada and Draxis Health
MILTON, ONTARIO -- (Marketwire) -- 11/28/12 -- Stellar Pharmaceuticals Inc. (OTCQB:SLXCF)(OTCBB:SLXCF)(PINKSHEETS:SLXCF) ("Stellar" or the "Company") and its operating division, Tribute Pharmaceuticals announced today the appointment of Dr. Bernard Chiasson, Ph.D. to the newly created position of Chief Scientific Officer. Dr. Chiasson is a trained neuroscientist and pharmacologist and will lead the scientific and regulatory affairs worldwide for Stellar's proprietary products as well as its growing portfolio of in-licensed products.
Dr. Chiasson brings to Stellar the valuable combination of expertise in medical science, business, and licensing, which he has translated into strong growth for numerous global healthcare companies. Dr. Chiasson recently served as Vice President, U.S. Strategic Regulatory and Global Medical Services at OptumInsight (Life Sciences Group), a division of UnitedHealth Group, a NYSE listed company with $100 billion in revenues. Prior to his position at OptumInsight, he was Director, Regional Medical Liaisons and Medical Services, North American Scientific Affairs for Amgen Canada, a division of Amgen, a NASDAQ listed biotech with annual revenues over $15 billion. Dr. Chiasson was also employed by Bayer Healthcare Canada, a division of Bayer AG, a global pharmaceutical company with over $38 billion in revenues, as Director, Scientific Development Biologic, Products for Canada, as part of the Canada, Japan and Developing Markets Group. In addition, he also served as Executive Director, Medical and Regulatory Affairs at the then publicly-held Draxis Health and began his industry career as a field-based Medical Liaison Specialist at Novartis Pharmaceuticals Canada, a division of Novartis AG, a NYSE listed healthcare company with $51 billion in annual revenues.
"Dr. Chiasson's expertise, knowledge and relationships in the global and North American healthcare market will be a great asset for Stellar as we actively expand our in-licensed product portfolio in the Canadian market and add additional distribution partners in gl obal markets including the U.S. for our proprietary Uracyst(R) and NeoVisc(R) products," stated Rob Harris, President and CEO of Stellar.
About Stellar Pharmaceuticals Inc.
Stellar and its operating division, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market.
Stellar markets Cambia(R) (diclofenac potassium for oral solution), Bezalip(R) SR (bezafibrate), Soriatane(R) (acitretin), NeoVisc(R) (1.0% sodium hyaluronate solution) a Uracyst(R) (sodium chondroitin sulfate solution 2%), Collatamp G(R) and Gelfoam(R) in the Canadian market. Additionally, NeoVisc(R) and Uracyst(R) are commercially available and are sold globally through various international partnerships.
For further information on Stellar, visit www.stellarpharma.com, or its operating division Tribute Pharmaceuticals, please visit www.tributepharma.com.
Stellar Pharmaceuticals' Forward Looking Statement
This press release contains certain forward-looking statements about Stellar as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties, Stellar actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including general economic conditions, the ability of Stellar to successfully integrate operations, and the timing of expenditures and expansion opportunities, any of which could cause actual results to vary materially from current results or anticipated future results. See Stellar's reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. Stellar assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time.
-- Soriatane and Bezalip are registered trademarks and under license from Actavis Group PTC ehf. -- Cambia is a registered trademark and under license from Nautilus Neurosciences, Inc. -- Collatamp G is a registered trademark an under license from EUSA Pharma (Europe) Limited. -- Gelfoam is a registered trademark of Pharmacia & Upjohn Company LLC, used under license by Pfizer Canada Inc.
Contacts: Stellar Pharmaceuticals Inc. Scott Langille CFO 519-434-1540 email@example.com
Stellar Pharmaceuticals Inc. Arnold Tenney Chairman 705-445-9505 www.stellarpharma.com
Hampton Growth Robert Haag 877-368-3566 firstname.lastname@example.org